NZ273208A - Suppressing a humoral immune response against a thymus dependant (TD) antigen - Google Patents

Suppressing a humoral immune response against a thymus dependant (TD) antigen

Info

Publication number
NZ273208A
NZ273208A NZ273208A NZ27320894A NZ273208A NZ 273208 A NZ273208 A NZ 273208A NZ 273208 A NZ273208 A NZ 273208A NZ 27320894 A NZ27320894 A NZ 27320894A NZ 273208 A NZ273208 A NZ 273208A
Authority
NZ
New Zealand
Prior art keywords
antigen
dependant
immune response
humoral immune
thymus
Prior art date
Application number
NZ273208A
Other languages
English (en)
Inventor
Randolph J Noelle
Teresa M Foy
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26813793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ273208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/232,929 external-priority patent/US5869049A/en
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of NZ273208A publication Critical patent/NZ273208A/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
NZ273208A 1993-09-02 1994-09-02 Suppressing a humoral immune response against a thymus dependant (TD) antigen NZ273208A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11599093A 1993-09-02 1993-09-02
US08/232,929 US5869049A (en) 1993-09-02 1994-04-25 Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
PCT/US1994/009872 WO1995006480A1 (en) 1993-09-02 1994-09-02 Methods of prolonged suppression of humoral immunity

Publications (1)

Publication Number Publication Date
NZ273208A true NZ273208A (en) 2000-12-22

Family

ID=26813793

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ273208A NZ273208A (en) 1993-09-02 1994-09-02 Suppressing a humoral immune response against a thymus dependant (TD) antigen

Country Status (14)

Country Link
EP (1) EP0742721B1 (el)
JP (1) JP2840131B2 (el)
CN (1) CN1137726C (el)
AT (1) ATE179616T1 (el)
AU (3) AU7643094A (el)
DE (1) DE69418349T2 (el)
DK (1) DK0742721T3 (el)
ES (1) ES2134954T3 (el)
FI (1) FI106927B (el)
GR (1) GR3030762T3 (el)
IL (1) IL110852A (el)
NO (1) NO321037B1 (el)
NZ (1) NZ273208A (el)
WO (1) WO1995006480A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
WO2000072882A1 (fr) * 1999-06-01 2000-12-07 Eisai Co., Ltd. Agents prophylactiques du purpura thrombocytopenique idiopathique
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
CA2408691A1 (en) 2000-05-12 2001-11-22 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
AU2015204503B2 (en) 2014-01-13 2020-07-09 Baylor Research Institute Novel vaccines against HPV and HPV-related diseases
CA2994825A1 (en) 2015-08-05 2017-02-09 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897983B1 (en) * 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU655349B2 (en) * 1992-02-17 1994-12-15 Kenji Nakamura An antibacterial porous inorganic capsule and a process for producing the same

Also Published As

Publication number Publication date
DE69418349T2 (de) 1999-09-09
NO960863L (no) 1996-04-30
GR3030762T3 (en) 1999-11-30
DE69418349D1 (de) 1999-06-10
JP2840131B2 (ja) 1998-12-24
FI960979A (fi) 1996-04-30
NO321037B1 (no) 2006-03-06
EP0742721A1 (en) 1996-11-20
AU734853B2 (en) 2001-06-21
NO960863D0 (no) 1996-03-01
FI960979A0 (fi) 1996-03-01
DK0742721T3 (da) 1999-11-01
JPH09502184A (ja) 1997-03-04
AU2004240180A1 (en) 2005-01-27
WO1995006480A1 (en) 1995-03-09
AU7643094A (en) 1995-03-22
AU2004240180B2 (en) 2007-08-09
ES2134954T3 (es) 1999-10-16
IL110852A0 (en) 1994-11-28
FI106927B (fi) 2001-05-15
IL110852A (en) 1999-05-09
CN1137726C (zh) 2004-02-11
AU1422099A (en) 1999-04-01
ATE179616T1 (de) 1999-05-15
CN1137758A (zh) 1996-12-11
EP0742721B1 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
AU4098797A (en) Imidazo(4,5-c)pyridin-4-amines
NZ273208A (en) Suppressing a humoral immune response against a thymus dependant (TD) antigen
GB9109525D0 (en) Portable high chair/booster seat
HUT53907A (en) Herbicides and process for producing alkoxy-1,2,4-triazolo(1,5-c)pyrimidine-2-sulfonamides used as active ingredient
EP0394441A4 (en) Back rest-carrying chair
IL85317A0 (en) System for protection of portable articles such as handbags against unauthorised use
CA2078549A1 (en) Multiple sclerosis t-cell receptor
ZA919435B (en) Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
AU2616788A (en) Device for use in the treatment of lymphocytes
AU2975692A (en) Expression vectors and their use in the preparation of HIV-resistant human cells for therapeutic applications
AU7169494A (en) Peptides for use in induction of T cell activation against HIV-1
AU9150591A (en) Device for generation of space charge in the atmosphere
AU2929089A (en) Seat adapted to the morphological attitudes of the user
AU572376B2 (en) Foldable carry chair for invalids
AU614418B2 (en) Steroids useful in the preparation of c20 through c26 amino steroids
AU3930689A (en) Partition and component for use in the partition
AU607859C (en) Shoulder and back support brace
IT8821313V0 (it) Dispositivo di bloccaggio per rotelle di poltrone scrivanie e simili.
IL85891A0 (en) Device for the generation of hot water and hot water delivery systems containing it
AU7850891A (en) Procedure for detecting and preparing anti-ige autoantibodies and use of these antibodies as active agents in diagnostic and therapeutic compositions
AU3514689A (en) Shoulder and back support brace
CS278188A1 (en) Arm-rest for armchair
AU8039094A (en) Partition and component for use in the partition
IL103865A0 (en) Expression vectors and their use in the preparation of hiv-resistant human cells for therapeutic applications
ITMI920811V0 (it) Schienale economico per poltrone per uso medico

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired